Neurology & CNS Deal Benchmarks
Deal benchmarks for Alzheimer's, Parkinson's, epilepsy, migraine, schizophrenia, and other neurological disorders. Benchmarks derived from 129 verified transactions.
129
Total Deals
$895M
Avg Upfront
6
Deal Types
100%
Terms Disclosed
Deal Structure Distribution
42
license
39
acquisition
25
collaboration
7
option
9
co development
Recent Deals with Disclosed Terms
| Parties | Type | Upfront | Total Value | Date |
|---|---|---|---|---|
AC Immune SA → Eli Lilly and Company Morphomer Tau | license | $10M | $1.7B | Apr 2026 |
Centessa Pharmaceuticals → Eli Lilly Cleminorexton (ORX750) — full company acquisition | acquisition | $6.3B | $7.8B | Mar 2026 |
Corium Therapeutics → Collegium Pharmaceutical Azstarys | acquisition | $650M | $785M | Mar 2026 |
Sangamo Therapeutics → Eli Lilly STAC-BBB AAV capsid | license | $18M | $1.4B | Mar 2026 |
Verve Therapeutics → Eli Lilly neurological gene-editing therapies | acquisition | $1.3B | $1.3B | Mar 2026 |
Zevra Therapeutics → Commave Therapeutics SA serdexmethylphenidate (SDX) portfolio | acquisition | $50M | $50M | Mar 2026 |
Rapport Therapeutics → Tenacia Biotechnology RAP-219 | license | $20M | $328M | Mar 2026 |
SciNeuro → Novartis amyloid beta-targeted antibody program | license | $165M | $1.7B | Jan 2026 |
Passage Bio → Seagen Anti-Orexin-101 | acquisition | $353M | $2.5B | Dec 2025 |
Adel → Sanofi antibody therapy | license | $80M | $1.0B | Dec 2025 |
Benchmark Your Neurology & CNS Deal
Get instant benchmarks for upfront payments, milestones, and royalties based on 129 verified neurology & cns transactions.
Run Neurology & CNS Benchmark